Learning from the past: Historical aspects of bacterial toxins as pharmaceuticals

Current Opinion in Microbiology

Volumn 15, Issue 3, 2012, Pages 292-299

  Pellett, Sabine ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN; SNARE PROTEIN; STREPTOKINASE; TUMOR NECROSIS FACTOR ALPHA;

ADRENERGIC SYSTEM; BLEPHAROSPASM; BOTULISM; CERVICAL DYSTONIA; CLOSTRIDIUM BOTULINUM; FOOD AND DRUG ADMINISTRATION; FOOD POISONING; HEMIFACIAL SPASM; HUMAN; HUNTINGTON CHOREA; HYPERHIDROSIS; MEAT; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MIGRAINE; MOTOR DYSFUNCTION; MYALGIA; NEUROMUSCULAR SYNAPSE; PAIN; REVIEW; SPASTICITY; STRABISMUS; STREPTOCOCCUS PYOGENES; STROKE; YELLOW FEVER;

BOTULINUM TOXINS; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS;

BACTERIA (MICROORGANISMS);

EID: 84864036102     PISSN: 13695274     EISSN: 18790364     Source Type: Journal    
DOI: 10.1016/j.mib.2012.05.005     Document Type: Review

References (53)

1. Kerner J. Vergiftung durch verdorbene Würste. Tübinger Blätter für Naturwissenschaften und Arzneykunde 1817, 3:1-25.
2. Kerner J. Neue Beobachtungen über Die in Würtemberg so Häufig Vorfallenden Tödtlichen Vergiftungen Durch Den Genuß Geräucherter Würste 1820, Osiander.
3. Kerner J. Das Fettgift Oder Die Fettsäure Und Ihre Wirkungen Auf Den Thierischen Organismus, Ein Beytrag Zur Untersuchung Des in Verdorbenen Würsten Giftig Wirkenden Stoffes. Cotta 1822.
4. Häfner S. Justinus Kerner's heroic experiments with botulinum toxin. Akt Neurol 2009, 36:412-417.
5. Müller H. Das Wurstgift. Deutsche Klinik 1869, 40:365-367. 381-383 (pulserial publication).
6. van Ermengem E. Classics in infectious diseases. A new anaerobic bacillus and its relation to botulism. Rev Infect Dis 1979, 1:701-719. Originally published as "Ueber einen neuen anaeroben Bacillus und seine Beziehungen zum Botulismus" in Zeitschrift fur Hygiene und Infektionskrankheiten 26: 1-56, 1897.
7. Ermengem E. Ueber einen neuen anaëroben Bacillus und seine Beziehungen zum Botulismus. Med Microbiol Immunol (Berl) 1897, 1-56.
8. Burke G.S. Notes on Bacillus botulinus. J Bacteriol 1919, 4. 555-570.1.
9. Burke G.S. The occurrence of Bacillus botulinus in nature. J Bacteriol 1919, 4:541-553.
10. Snipe P.T., Sommer H. Studies on botulinus toxin: 3. Acid precipitation of botulinus toxin. J Infect Dis 1928, 43:152-160. [with Discussion].
11. Lamanna C., Eklund H.W., McElroy O.E. Botulinum toxin (Type A); including a study of shaking with chloroform as a step in the isolation procedure. J Bacteriol 1946, 52:1-13.
12. Burgen A.S., Dickens F., Zatman L.J. The action of botulinum toxin on the neuro-muscular junction. J Physiol 1949, 109:10-24.
13. Boor A.K., Tresselt H.B., Schantz E.J. Effects of salts and colloids on potency of botulinum toxin. Proc Soc Exp Biol Med 1955, 89:270-272.
14. Buehler H.J., Schantz E.J., Lamanna C. The elemental and amino acid composition of crystalline Clostridium botulinum type A toxin. J Biol Chem 1947, 169:295-302.
15. Lamanna C., Spero L., Schantz E.J. Dependence of time to death on molecular size of botulinum toxin. Infect Immun 1970, 1:423-424.
16. Schantz E.J. Some chemical and physical properties of Clostridium botulinum toxins in culture. Jpn J Microbiol 1967, 11:380-383.
17. Schantz E.J., Stefanye D., Spero L. Observations on the fluorescence and toxicity of botulinum toxin. J Biol Chem 1960, 235:3489-3491.
18. Stefanye D., Schantz E.J., Spero L. Amino acid composition of crystalline botulinum toxin, type A. J Bacteriol 1967, 94:277-278.
19. Weil L., Seibles T.S., Spero L., Schantz E.J. Photooxidation of crystalline Clostridium botulinum type A toxin in the presence of methylene blue. Arch Biochem Biophys 1957, 68:308-313.
20. Drachman D.B. Botulinum toxin as a tool for research on the nervous system. Neuropoisons. Their Physiological Actions 1971, 325-347. Plenum. L.L. Simpson (Ed.).
21. Scott A.B., Rosenbaum A., Collins C.C. Pharmacologic weakening of extraocular muscles. Invest Ophthalmol 1973, 12:924-927.
22. Scott A.B. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. J Pediatr Ophthalmol Strabismus 1980, 17:21-25.
23. Cartee T.V., Monheit G.D. An overview of botulinum toxins: past, present, and future. Clin Plast Surg 2011, 38:409-426. vi.
24. Brashear A. Botulinum toxin type A: exploring new indications. Drugs Today (Barc) 2010, 46:671-682.
25. Peck M.W. Biology and genomic analysis of Clostridium botulinum. Adv Microb Physiol 2009, 55:183-265. 320.
26. Johnson E.A., Montecucco C. Chapter 11 Botulism. Handbook of Clinical Neurology 2008, 333-368. Elsevier. G. Andrew, Engel (Eds.).
27. Montal M. Botulinum neurotoxin: a marvel of protein design. Annu Rev Biochem 2010, 79:591-617.
28. Huang P.P., Khan I., Suhail M.S., Malkmus S., Yaksh T.L. Spinal botulinum neurotoxin B: effects on afferent transmitter release and nociceptive processing. PLoS ONE 2011, 6:e19126.
29. Lee W.H., Shin T.J., Kim H.J., Lee J.K., Suh H.W., Lee S.C., Seo K. Intrathecal administration of botulinum neurotoxin type A attenuates formalin-induced nociceptive responses in mice. Anesth Analg 2011, 112:228-235.
30. Marinelli S., Luvisetto S., Cobianchi S., Makuch W., Obara I., Mezzaroma E., Caruso M., Straface E., Przewlocka B., Pavone F. Botulinum neurotoxin type A counteracts neuropathic pain and facilitates functional recovery after peripheral nerve injury in animal models. Neuroscience 2010, 171:316-328.
31. Pickett A., Perrow K. Towards new uses of botulinum toxin as a novel therapeutic tool. Toxins (Basel) 2011, 3:63-81.
32. Yeh F.L., Zhu Y., Tepp W.H., Johnson E.A., Bertics P.J., Chapman E.R. Retargeted clostridial neurotoxins as novel agents for treating chronic diseases. Biochemistry 2011, 50:10419-10421.
33. Singh B.R., Thirunavukkarasu N., Ghosal K., Ravichandran E., Kukreja R., Cai S., Zhang P., Ray R., Ray P. Clostridial neurotoxins as a drug delivery vehicle targeting nervous system. Biochimie 2010, 92:1252-1259.
34. Bernardes N., Seruca R., Chakrabarty A.M., Fialho A.M. Microbial-based therapy of cancer: current progress and future prospects. Bioeng Bugs 2010, 1:178-190.
35. Kapoor V.K. Natural toxins and their therapeutic potential. Indian J Exp Biol 2010, 48:228-237.
36. Lorberboum-Galski H. Human toxin-based recombinant immunotoxins/chimeric proteins as a drug delivery system for targeted treatment of human diseases. Expert Opin Drug Deliv 2011, 8:605-621.
37. Pornpattananangkul D., Zhang L., Olson S., Aryal S., Obonyo M., Vecchio K., Huang C.M., Zhang L. Bacterial toxin-triggered drug release from gold nanoparticle-stabilized liposomes for the treatment of bacterial infection. J Am Chem Soc 2011, 133:4132-4139.
38. Smith C.L., Ghosh J., Elam J.S., Pinkner J.S., Hultgren S.J., Caparon M.G., Ellenberger T. Structural basis of Streptococcus pyogenes immunity to its NAD+ glycohydrolase toxin. Structure 2011, 19:192-202.
39. Zielinski R., Lyakhov I., Hassan M., Kuban M., Shafer-Weaver K., Gandjbakhche A., Capala J. HER2-affitoxin: a potent therapeutic agent for the treatment of HER2-overexpressing tumors. Clin Cancer Res 2011, 17:5071-5081.
40. Levine S.R. Thrombolytic therapy for stroke: the new paradigm. Hosp Pract (Minneap) 1997, 32:57-64. 69-73.
41. Maseri A., Andreotti F. Targeting new thrombolytic regimens at specific patient groups: implications for research and cost-containment. Eur Heart J 1997, 18(Suppl F):F28-F35.
42. Robertson C.E., Garza I. Critical analysis of the use of onabotulinumtoxinA (botulinum toxin type A) in migraine. Neuropsychiatr Dis Treat 2012, 8:35-48.
43. Alexiades-Armenakas M. Retrograde transport and transcytosis of botulinum toxin serotypes to the brain: analysis of potential neurotoxicity. J Drugs Dermatol 2008, 7:1006-1007.
44. Antonucci F., Rossi C., Gianfranceschi L., Rossetto O., Caleo M. Long-distance retrograde effects of botulinum neurotoxin A. J Neurosci 2008, 28:3689-3696.
45. Matak I., Bach-Rojecky L., Filipovic B., Lackovic Z. Behavioral and immunohistochemical evidence for central antinociceptive activity of botulinum toxin A. Neuroscience 2011, 186:201-207.
46. Filipovic B., Matak I., Bach-Rojecky L., Lackovic Z. Central action of peripherally applied botulinum toxin type a on pain and dural protein extravasation in rat model of trigeminal neuropathy. PLoS ONE 2012, 7:e29803.
47. Restani L., Antonucci F., Gianfranceschi L., Rossi C., Rossetto O., Caleo M. Evidence for anterograde transport and transcytosis of botulinum neurotoxin A (BoNT/A). J Neurosci 2011, 31:15650-15659.
48. Torii Y., Akaike N., Harakawa T., Kato K., Sugimoto N., Goto Y., Nakahira S., Kohda T., Kozaki S., Kaji R., Ginnaga A. Type A1 but not type A2 botulinum toxin decreases the grip strength of the contralateral foreleg through axonal transport from the toxin-treated foreleg of rats. J Pharmacol Sci 2011, 117:275-285.
49. Eleopra R., Tugnoli V., Quatrale R., Rossetto O., Montecucco C. Different types of botulinum toxin in humans. Mov Disord 2004, 19(Suppl. 8):S53-S59.
50. Sloop R.R., Cole B.A., Escutin R.O. Human response to botulinum toxin injection: type B compared with type A. Neurology 1997, 49:189-194.
51. Keller J.E. Recovery from botulinum neurotoxin poisoning in vivo. Neuroscience 2006, 139:629-637.
52. Foran P.G., Mohammed N., Lisk G.O., Nagwaney S., Lawrence G.W., Johnson E., Smith L., Aoki K.R., Dolly J.O. Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared with the long lasting type A. Basis for distinct durations of inhibition of exocytosis in central neurons. J Biol Chem 2003, 278:1363-1371.
53. Gupta A., Sumner C.J., Castor M., Maslanka S., Sobel J. Adult botulism type F in the United States, 1981-2002. Neurology 2005, 65:1694-1700.